The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

ABSTRACT: During the past 20 years our understanding of the control of breast tumor development, growth and survival has changed dramatically. The once long forgotten application of high dose synthetic estrogen therapy as the first chemical therapy to treat any cancer has been resurrected, refined and reinvented as the new biology of estrogen-induced apoptosis. High dose estrogen therapy was cast aside once tamoxifen, from its origins as a failed "morning after pill", was reinvented as the first targeted therapy to treat any cancer. The current understanding of the mechanism of estrogen-induced apoptosis is described as a consequence of acquired resistance to long term antihormone therapy in estrogen receptor (ER) positive breast cancer. The ER signal transduction pathway remains a target for therap

SUBMITTER: Fan P 

PROVIDER: S-EPMC4760743 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature